{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:08:24Z","timestamp":1763132904216,"version":"3.45.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12325-025-03392-4","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:23:41Z","timestamp":1761294221000},"page":"5950-5959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Visualizing Improvements in Airway Dysfunction After Inhaled Therapy in Patients With Uncontrolled Asthma: A Narrative Review"],"prefix":"10.1007","volume":"42","author":[{"given":"Sam","family":"Tcherner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Mozaffaripour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cory","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Parraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"3392_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1080\/02770903.2017.1316394","volume":"55","author":"LK Lee","year":"2018","unstructured":"Lee LK, Obi E, Paknis B, Kavati A, Chipps B. Asthma control and disease burden in patients with asthma and allergic comorbidities. J Asthma. 2018;55:208\u201319.","journal-title":"J Asthma"},{"key":"3392_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.anai.2020.12.015","volume":"126","author":"J Oppenheimer","year":"2021","unstructured":"Oppenheimer J, Slade DJ, Hahn BA, et al. Real-world evidence: patient views on asthma in respiratory specialist clinics in America. Ann Allergy Asthma Immunol. 2021;126:385-393 e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3392_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106368","volume":"180","author":"S Safavi","year":"2021","unstructured":"Safavi S, Munidasa S, Zanette B, et al. Evaluating post-bronchodilator response in well-controlled paediatric severe asthma using hyperpolarised 129Xe-MRI: a pilot study. Respir Med. 2021;180:106368.","journal-title":"Respir Med"},{"key":"3392_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2025.07.002","author":"D Toumpanakis","year":"2025","unstructured":"Toumpanakis D, Kim Y, Usmani OS. Small airway disease in COPD patients: a Q&A approach for everyday clinical practice. Chest. 2025. https:\/\/doi.org\/10.1016\/j.chest.2025.07.002.","journal-title":"Chest"},{"key":"3392_CR5","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.chest.2019.02.403","volume":"155","author":"S Svenningsen","year":"2019","unstructured":"Svenningsen S, Haider E, Boylan C, et al. CT and functional MRI to evaluate airway mucus in severe asthma. Chest. 2019;155:1178\u201389.","journal-title":"Chest"},{"key":"3392_CR6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1183\/13993003.00393-2016","volume":"48","author":"S Svenningsen","year":"2016","unstructured":"Svenningsen S, Nair P, Guo F, McCormack DG, Parraga G. Is ventilation heterogeneity related to asthma control? Eur Respir J. 2016;48:370\u20139.","journal-title":"Eur Respir J"},{"key":"3392_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1152\/japplphysiol.01031.2017","volume":"125","author":"HM Young","year":"2018","unstructured":"Young HM, Guo F, Eddy RL, Maksym G, Parraga G. Oscillometry and pulmonary MRI measurements of ventilation heterogeneity in obstructive lung disease: relationship to quality of life and disease control. J Appl Physiol (1985). 2018;125:73\u201385.","journal-title":"J Appl Physiol (1985)"},{"key":"3392_CR8","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/jmri.24111","volume":"38","author":"S Svenningsen","year":"2013","unstructured":"Svenningsen S, Kirby M, Starr D, et al. Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation. J Magn Reson Imaging. 2013;38:1521\u201330.","journal-title":"J Magn Reson Imaging"},{"key":"3392_CR9","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/jmri.27662","volume":"54","author":"DG Mummy","year":"2021","unstructured":"Mummy DG, Coleman EM, Wang Z, et al. Regional gas exchange measured by (129) Xe magnetic resonance imaging before and after combination bronchodilators treatment in chronic obstructive pulmonary disease. J Magn Reson Imaging. 2021;54:964\u201374.","journal-title":"J Magn Reson Imaging"},{"key":"3392_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1148\/radiol.2019190420","volume":"293","author":"RL Eddy","year":"2019","unstructured":"Eddy RL, Svenningsen S, Licskai C, McCormack DG, Parraga G. Hyperpolarized helium 3 MRI in mild-to-moderate asthma: prediction of postbronchodilator reversibility. Radiology. 2019;293:212\u201320.","journal-title":"Radiology"},{"key":"3392_CR11","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13955","volume":"7","author":"RL Eddy","year":"2019","unstructured":"Eddy RL, Westcott A, Maksym GN, Parraga G, Dandurand RJ. Oscillometry and pulmonary magnetic resonance imaging in asthma and COPD. Physiol Rep. 2019;7:e13955.","journal-title":"Physiol Rep"},{"key":"3392_CR12","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.acra.2017.04.012","volume":"24","author":"DPI Capaldi","year":"2017","unstructured":"Capaldi DPI, Sheikh K, Eddy RL, et al. Free-breathing functional pulmonary MRI: response to bronchodilator and bronchoprovocation in severe asthma. Acad Radiol. 2017;24:1268\u201376.","journal-title":"Acad Radiol"},{"key":"3392_CR13","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1148\/radiol.2017160532","volume":"284","author":"FC Horn","year":"2017","unstructured":"Horn FC, Marshall H, Collier GJ, et al. Regional ventilation changes in the lung: treatment response mapping by using hyperpolarized gas MR imaging as a quantitative biomarker. Radiology. 2017;284:854\u201361.","journal-title":"Radiology"},{"key":"3392_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1148\/radiol.12120485","volume":"265","author":"M Kirby","year":"2012","unstructured":"Kirby M, Svenningsen S, Owrangi A, et al. Hyperpolarized 3He and 129Xe MR imaging in healthy volunteers and patients with chronic obstructive pulmonary disease. Radiology. 2012;265:600\u201310.","journal-title":"Radiology"},{"key":"3392_CR15","unstructured":"Polarean Imaging Plc. FDA Approves Polarean\u2019s XENOVIEW\u2122 (xenon Xe 129 hyperpolarized) for use with MRI for the evaluation of lung ventilation; 2022. https:\/\/polarean.com\/wp-content\/uploads\/2022\/12\/POLX-FDA-Approves-XENOVIEW%E2%84%A2-hyperpolarized-Xe-12 (accessed 20 Aug 2025). https:\/\/polarean.com\/wp-content\/uploads\/2022\/12\/POLX-FDA-Approves-XENOVIEW%E2%84%A2-hyperpolarized-Xe-129.pdf."},{"key":"3392_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15040474","author":"JL MacLeod","year":"2025","unstructured":"MacLeod JL, Khan HM, Franklin A, Myc L, Shim YM. Hyperpolarized Xenon-129 MRI: narrative review of clinical studies, testing, and implementation of advanced pulmonary in vivo imaging and its diagnostic applications. Diagnostics. 2025. https:\/\/doi.org\/10.3390\/diagnostics15040474.","journal-title":"Diagnostics"},{"key":"3392_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/resp.14197","volume":"27","author":"HK Kooner","year":"2022","unstructured":"Kooner HK, McIntosh MJ, Desaigoudar V, et al. Pulmonary functional MRI: detecting the structure-function pathologies that drive asthma symptoms and quality of life. Respirology. 2022;27:114\u201333.","journal-title":"Respirology"},{"key":"3392_CR18","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00785-2020","author":"GT Mussell","year":"2021","unstructured":"Mussell GT, Marshall H, Smith LJ, et al. Xenon ventilation MRI in difficult asthma: initial experience in a clinical setting. ERJ Open Res. 2021. https:\/\/doi.org\/10.1183\/23120541.00785-2020.","journal-title":"ERJ Open Res"},{"key":"3392_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.acra.2020.04.025","volume":"28","author":"S Svenningsen","year":"2021","unstructured":"Svenningsen S, McIntosh M, Ouriadov A, et al. Reproducibility of hyperpolarized (129)Xe MRI ventilation defect percent in severe asthma to evaluate clinical trial feasibility. Acad Radiol. 2021;28:817\u201326.","journal-title":"Acad Radiol"},{"key":"3392_CR20","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.01333-2024","author":"A Mozaffaripour","year":"2025","unstructured":"Mozaffaripour A, Tcherner S, Durom E, et al. Airway mucus and 129Xe MRI ventilation after single-inhaler triple therapy in asthma. ERJ Open Res. 2025. https:\/\/doi.org\/10.1183\/23120541.01333-2024.","journal-title":"ERJ Open Res"},{"key":"3392_CR21","unstructured":"Sharma M, Kooner HK, Tcherner S, et al. C71. Asthma clinical phenotypes and therapies, p. A6362-A."},{"key":"3392_CR22","doi-asserted-by":"crossref","first-page":"A5214","DOI":"10.1164\/rccm.202402-0353LE","volume":"209","author":"A Mozaffaripour","year":"2024","unstructured":"Mozaffaripour A, Tcherner S, Sharma M, et al. 129Xe MRI and oscillometry evidence of improved small airways dysfunction after 6-weeks ICS\/LABA\/LAMA therapy in moderate asthma [abstract]. Am J Respir Crit Care Med. 2024;209:A5214.","journal-title":"Am J Respir Crit Care Med"},{"key":"3392_CR23","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1016\/j.acra.2023.03.010","volume":"30","author":"MJ McIntosh","year":"2023","unstructured":"McIntosh MJ, Biancaniello A, Kooner HK, et al. (129)Xe MRI ventilation defects in asthma: what is the upper limit of normal and minimal clinically important difference? Acad Radiol. 2023;30:3114\u201323.","journal-title":"Acad Radiol"},{"key":"3392_CR24","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention; 2024. https:\/\/ginasthma.org\/reports\/. Accessed 14 June 2024."},{"key":"3392_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","volume":"9","author":"LA Lee","year":"2021","unstructured":"Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9:69\u201384.","journal-title":"Lancet Respir Med"},{"key":"3392_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.chest.2022.03.003","volume":"162","author":"MJ McIntosh","year":"2022","unstructured":"McIntosh MJ, Kooner HK, Eddy RL, et al. Asthma control, airway mucus, and (129)Xe MRI ventilation after a single benralizumab dose. Chest. 2022;162:520\u201333.","journal-title":"Chest"},{"key":"3392_CR27","unstructured":"US Clinical Trials Registry. Evaluating the effect of benralizumab in severe, poorly-controlled eosinophilic asthma using inhaled hyperpolarized 129-Xenon MRI (AERFLO); 2024. https:\/\/ichgcp.net\/clinical-trials-registry\/NCT03733535 (accessed 22 May 2025)."},{"key":"3392_CR28","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1164\/rccm.202306-1102LE","volume":"208","author":"S Svenningsen","year":"2023","unstructured":"Svenningsen S, Kjarsgaard M, Haider E, et al. Effects of dupilumab on mucus plugging and ventilation defects in patients with moderate-to-severe asthma: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2023;208:995\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"3392_CR29","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1002\/mrm.28985","volume":"86","author":"PJ Niedbalski","year":"2021","unstructured":"Niedbalski PJ, Hall CS, Castro M, et al. Protocols for multi-site trials using hyperpolarized (129) Xe MRI for imaging of ventilation, alveolar-airspace size, and gas exchange: a position paper from the (129) Xe MRI clinical trials consortium. Magn Reson Med. 2021;86:2966\u201386.","journal-title":"Magn Reson Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03392-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03392-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03392-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:04:09Z","timestamp":1763132649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03392-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3392"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03392-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sam Tcherner, Ali Mozaffaripour, and Cory Yamashita have no conflicts of interest pertaining to the work. Grace Parraga has received speaking honoraria from GSK, AstraZeneca, Polarean, and Sanofi, as well as study funding from AstraZeneca and GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As a narrative review, this article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. As such, no additional approvals or informed consent were obtained above those collected as part of the original clinical studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}